Aller au contenu principal

 Articles scientifiques

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Perez EA, Awada A, OShaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J
Année : 2015
Journal : Lancet Oncol
Volume : 16
Pages : 1556-68

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart-Gebhart M
Année : 2015
Journal : Ann Oncol
Volume : 26
Pages : 1547-73

A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.

Auteurs : Gil T, Aoun F, Cabri P, Maisonobe P, Van Velthoven R
Année : 2015
Journal : Ther Adv Urol
Volume : 7(3)
Pages : 116-24

Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal.

Auteurs : Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA
Année : 2015
Journal : Breast
Volume : 24(4)
Pages : 513-23

'New' metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy, Breast Cancer Research 2015, 17: 150

Auteurs : Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder T, Olivo M, O Shaughnessy J, Jove M, Perez EA
Année : 2015
Journal : Breast Cancer Res
Volume : 17
Pages : 150

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart-Gebhart M, Sotiriou C
Année : 2015
Journal : BMC Med
Volume : 13(1)
Pages : 177

Targeted agents for cancer treatment during pregnancy.

Auteurs : Lambertini M, Peccatori FA, Azim HA
Année : 2015
Journal : Cancer Treat Rev
Volume : 41(4)
Pages : 301-309

Checkpoint inhibitors in bladder and renal cancers: results and perspectives.

Auteurs : Aoun F, Kourie HR, Sideris S, Roumeguère T, Van Velthoven R, Gil T
Année : 2015
Journal : Immunotherapy
Volume : 7
Pages : 1259-71

Thrombo-embolic events in cancer patients with impaired renal function

Auteurs : Elalamy I, Canon JL, Bols A, Lybaert W, Duck L, Jochmans K, Bosquée L, Peeters M, Awada A, Clement P, Holbrechts S, Baurain JF, Mebis J, Nortier J
Année : 2015
Journal : Belgian J Medical Oncology
Volume : 9(2)
Pages : 53-60

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Auteurs : Sonnenblick A, Francis PA, Azim HA, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart-Gebhart M, Crown J
Année : 2015
Journal : Eur. J. Cancer
Volume : 51(12)
Pages : 1481-9

New approaches for improving outcomes in breast cancer in Europe.

Auteurs : Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart-Gebhart M
Année : 2015
Journal : Breast
Volume : 24(4)
Pages : 321-330

Novel mechanisms and approaches in the medical therapy of solid cancers.

Auteurs : Awada G, Kourie HR, Awada A
Année : 2015
Journal : Discov Med
Volume : 20
Pages : 33-41

Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials, Next Generation Sequencing in Cancer Research 2015,

Auteurs : Thomas F, Awada A
Année : 2015
Journal : Book
Volume : 2
Pages : 19-37

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

Auteurs : OSullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber Rd
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(24)
Pages : 2600-8

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Auteurs : Boyle FM, Smith IE, + collaborators (among others :, Piccart-Gebhart M, Finkelstein D
Année : 2015
Journal : Eur. J. Cancer
Volume : 51(6)
Pages : 685-96

Genomic aberrations in young and elderly  breast cancer patients.

Auteurs : Azim HA, Nguyen B, Brohée S, Zoppoli G, Sotiriou C
Année : 2015
Journal : BMC Med
Volume : 13
Pages : 266

Epidemiological risk factors for breast cancer in premenopausal women, Maternal Medicine 2015 (ebook; McGraw-Hill Education / Medical; 1 edition (22 July 2015))

Auteurs : Pinto AC, Azim HA, Lambertini M, Awada A, Ibrahim NK
Année : 2015
Journal : Book
Volume : -
Pages : -

Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicentre prospective study.

Auteurs : Baitar A, Kenis C, Moor R, Decoster L, Luce S, Bron D, Van Rijswijk R, Rasschaert M, Langenaeken C, Jerusalem G, Lobelle JP, Flamaing J, Milisen K, Wildiers H
Année : 2015
Journal : J Geriatr Oncol
Volume : 6(5)
Pages : 401-10

No significant viral transcription detected in whole breast cancer transcriptomes.

Auteurs : Fimereli D, Gacquer D, Fumagalli D, Salgado R, Rothé F, Larsimont D, Sotiriou C, Detours V
Année : 2015
Journal : BMC Cancer
Volume : 15(null)
Pages : 147

Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?

Auteurs : Gingras I, Salgado R, Ignatiadis M
Année : 2015
Journal : Curr Opin Oncol
Volume : 27
Pages : 560-7